Barclays
CASC

Barclays’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Barclays’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-900
Closed -$5K – 6852
2016
Q1 		$5K Sell
900
-167
-16% -$1.29K ﹤0.01% 5688
2015
Q4 		$13K Sell
1,067
-1,033
-49% -$17.8K ﹤0.01% 5334
2015
Q3 		$25K Sell
2,100
-7,433
-78% -$152K ﹤0.01% 5363
2015
Q2 		$172K Buy
9,533
+7,233
+314% +$114K ﹤0.01% 4248
2015
Q1 		$14K Buy
+2,300
New +$22.6K ﹤0.01% 6061
2014
Q4 		– Sell
-250
Closed -$2K – 7793
2014
Q3 		$2K Sell
250
-367
-59% -$5.61K ﹤0.01% 7457
2014
Q2 		$11K Sell
617
-1,933
-76% -$34.1K ﹤0.01% 6806
2014
Q1 		$31K Sell
2,550
-101,350
-98% -$1.66M ﹤0.01% 6355
2013
Q4 		$623K Sell
103,900
-417
-0.4% -$4.66K ﹤0.01% 3877
2013
Q3 		$1.25M Sell
104,317
-7,383
-7% -$77.7K ﹤0.01% 3096
2013
Q2 		$1.05M Buy
+111,700
New +$1.43M ﹤0.01% 3292

Barclays's CASC Position: Q1 2018 in Review

Barclays sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 6,125 shares — an estimated $23K sold.

Barclays first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $126K in Q2 2013. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Barclays reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Barclays sold 6,125 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $23K.
  • Barclays first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
  • Barclays's Cascadian Therapeutics, Inc. position peaked at $126K in Q2 2013.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.